Evidence map›Paper›PMID 34654889›Full record

ReviewOncogene2021

Liprins in oncogenic signaling and cancer cell adhesion.

Henna Pehkonen, Ivan de Curtis, Outi Monni

Open access · hybridAbstract readReview
In one paragraph

Review in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Liprin-α family proteins and their cellular functions.The Journal of biological chemistry · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Henna PehkonenApplied Tumor Genomics Research Program and Department of Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-9615-384X
Ivan de CurtisCell Adhesion Unit, Division of Neuroscience, IRCSS San Raffaele Scientific Institute, San Raffaele Vita-Salute University, Milan, Italy.
Outi MonniApplied Tumor Genomics Research Program and Department of Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland. outi.monni@helsinki.fi.ORCID http://orcid.org/0000-0002-2319-8799
University of Helsinki · FIVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liprins are a multifunctional family of scaffold proteins, identified by their involvement in several important neuronal functions related to signaling and organization of synaptic structures. More recently, the knowledge on the liprin family has expanded from neuronal functions to processes relevant to cancer progression, including cell adhesion, cell motility, cancer cell invasion, and signaling. These proteins consist of regions, which by prediction are intrinsically disordered, and may be involved in the assembly of supramolecular structures relevant for their functions. This review summarizes the current understanding of the functions of liprins in different cellular processes, with special emphasis on liprins in tumor progression. The available data indicate that liprins may be potential biomarkers for cancer progression and may have therapeutic importance.

Indexed as

Biomarkers, TumorCell AdhesionDisease ProgressionGene Expression Regulation, NeoplasticHumansMultigene FamilyNeoplasmsNuclear Matrix-Associated ProteinsSignal TransductionBiomarkers, TumorNuclear Matrix-Associated Proteins

Identifiers

PMID34654889
PMCPMC8602034
OpenAlexW3206526835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.